Premenstrual dysphoric disorder (PMDD) symptoms are eliminated by ovarian suppression, stimulated by administration of ovarian steroids, yet appear in the context of levels of ovarian steroids indistinguishable from those in women without PMDD. Thus PMDD symptoms could be precipitated by either an acute change in the levels of ovarian steroids, or that stable levels of ovarian steroids above a critical threshold play a permissive role in the expression of an underlying infradian affective “pacemaker.” In this study, we attempted to define the kinetics of the ovarian steroid event relevant to triggering of PMDD symptoms.
We studied 22 women with PMDD, aged 30 to 50 years. Twelve women who experienced symptom remission after 2–3 months of GnRH agonist-induced ovarian suppression (leuprolide) then received one month of single-blind(participant only) placebo and then three months of continuous combined estradiol/progesterone. Primary outcome measure was the Rating for Premenstrual Tension observer rater- and self-ratings completed every two weeks during clinic visits. Multivariate repeated measure ANOVA for mixed models was employed.
Both Premenstrual Tension -self and –rater scores were significantly increased (more symptomatic) during the first month of combined estradiol/progesterone compared with all other months (i.e., last month of leuprolide alone (p=.0003,p<.0001, respectively), placebo(p=.0015,p=.0013, respectively), and 2nd month of estradiol/progesterone (p=.0014,p<.0001, respectively), and 3rd month of estradiol/progesterone (p=.0006,p<.0001, respectively). There were no significant differences in symptom severity scores (Premenstrual Tension -self, –rater)between the last month of leuprolide alone and the placebo month(p=.609, p=.106, respectively), 2nd month of estradiol/progesterone (p=.639, p=.524, respectively) and 3rd month of estradiol/progesterone (p=.99, p=.812, respectively). Finally, Premenstrual Tension scores in the 2nd and 3rd estradiol/progesterone months did not significantly differ.
We demonstrated that the change in levels of estradiol/progesterone from low to high, and not the steady state levels, was associated with the onset of PMDD symptoms. Therapeutic efforts to modulate the change in steroid levels proximate to ovulation merit further study.